
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is expected to be successful in expanding their product line and reaching their sales goal of $250 million by 2027 through driving sales of existing products and acquiring new ones. They have obtained a new J-code for one of their drugs, contributing to projected revenue of $365 million in 2026, but face potential risks such as unexpected outcomes, regulatory uncertainty, and competition. The company remains focused on promoting their current products and turning interest into sales.
Bears say
Harrow is facing declining revenues due to non-recurring gross-to-net adjustments and an overall operating and net loss. While management expects to normalize these adjustments in the next quarter, the current guidance for 2026 reaffirms a relatively stagnant revenue forecast. In order to compete in the competitive and constantly advancing eyecare market, Harrow will need to acquire additional products to diversify their portfolio and maintain growth in the future.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares